FDA approves nogapendekin alfa inbakicept-pmln for bladder cancer
On April 22, 2024, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC) for non-muscle invasive bladder cancer.
On April 22, 2024, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC) for non-muscle invasive bladder cancer.
PURPOSE Nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors…
Overview The 12th Annual Symposium on Global Cancer Research (ASGCR) will be held virtually May 6 – May 9, 2024 [8AM-12PM Eastern Time each day]. See…
AACR CEO Margaret Foti, PhD, MD (hc) (back left), with cancer survivor Cayden Addison (front left), his brother Christian (front right), and his mother Courtney…
Learn how smoking cigarettes can damage important parts of your eyes necessary for maintaining clear eyesight and vision.
This cohort study assesses treatment patterns and attrition rates in patients with advanced urothelial carcinoma in US oncology clinics.
This cohort study assesses treatment patterns and attrition rates in patients with advanced urothelial carcinoma in US oncology clinics.
June 27-29 (EDT), June 28-30 (JST), 2024Kyoto Tokyu HotelKyoto, Japan On-Demand: On-demand streaming will be available until September 30, 23:59 (JST). Conference Chairs Luis A.…
Background: Despite advances in the treatment of early triple-negative breast cancer (TNBC), patients with residual invasive disease after neoadjuvant therapy h…